Xiaohu Deng
Technik-/Wissenschafts-/F&E-Leiter bei Vividion Therapeutics, Inc.
Aktive Positionen von Xiaohu Deng
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Karriereverlauf von Xiaohu Deng
Ehemalige bekannte Positionen von Xiaohu Deng
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | - | - |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
Ausbildung von Xiaohu Deng
| Emory University | Doctorate Degree |
| Fudan University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| China | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| KURA ONCOLOGY, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
- Börse
- Insiders
- Xiaohu Deng
- Erfahrung